FRC schreef op 28 februari 2014 08:06:
Salix Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript
Thursday, February 27, 8:50 PM ET | About: SLXP
Irina Rivkind - Cantor Fitzgerald & Co., Research Division
And then just a quick follow-up on the RUCONEST PDUFA, that was delayed. Is that because FDA wants additional data or something else?
William P. Forbes
No. They didn't -- I mean, if you mean by additional data, were there additional work that needed to be done, no. But there's some additional requests that they had, and those were submitted and they took the opportunity to extend the PDUFA by 3 months. And so I think, in a way, maybe that's -- we like to look the glass half-full, maybe that's a positive for us because they've requested information. We submitted it, and they've taken a little additional time.
Operator
We'll take the next question from Tim Lugo with Blair.
Tim Lugo - William Blair & Company L.L.C., Research Division
For -- I guess, following up on RUCONEST. Are you prepared to launch the product yourself? I know it's a bit outside the GI or primary care focus and HIV is pretty competitive these days.
Carolyn J. Logan
We -- it's a small number of physicians. So we certainly could do this ourselves, and we're looking very strongly at that. I don't know if we have 100% made that decision yet, but I think we are strongly leaning in that direction.
Salix.
persconferentie 27 02 2014